Pharmaceutical Information |
Drug Name |
Aclidinium |
Drug ID |
BADD_D02465 |
Description |
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. |
Indications and Usage |
Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. |
Marketing Status |
Not Available |
ATC Code |
Not Available |
DrugBank ID |
DB08897
|
KEGG ID |
Not Available
|
MeSH ID |
Not Available
|
PubChem ID |
11434515
|
TTD Drug ID |
D0VP1V
|
NDC Product Code |
Not Available |
Synonyms |
Not Available |
|
Chemical Information |
Molecular Formula |
C26H30NO4S2+ |
CAS Registry Number |
727649-81-2 |
SMILES |
C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5 |
Chemical Structure |
|
|
ADR Related Proteins Induced by Drug |
ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
Not Available | Not Available | Not Available | Not Available | Not Available |
|
ADRs Induced by Drug |
|